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sthma is a complex disorder characterized by intermit- 
tent, reversible airway obstruction, and by airway hy- 
perresponsiveness and inflammation.  Although its  cause(s) 
remain unknown, we now recognize that asthma is a syn- 
drome whose common pathologic expression is inflamma- 
tion of the airways.  The airways of patients with even mild 
asthma are inflamed, and some data suggest that the severity 
of the asthma parallels the degree of inflammation (1-3). 
The airway inflammation of asthma is unique in that the 
airway wall is infiltrated by T  lymphocytes bearing the T 
helper type 2  phenotype (4)  and by eosinophils and mast 
ceils (2, 5, 6). Each of these cells is thought to contribute to 
the  physiologic changes  that  characterize asthma  (Fig.  1). 
The TH2 lymphocytes produce a limited panel ofcytokines 
including  IL-3,  IL-4,  IL-5,  and  GM-CSF.  Although  the 
primary signals resulting in the infiltration of the asthmatic 
airways by this lymphocyte subset have not yet been identi- 
fied, a number of models have been proposed based on the 
concept that  the  inflammtory process  is  triggered by the 
presentation of a restricted panel of antigens in the presence 
of appropriate cytokines. The net effect of antigen presen- 
tation in this microenvironment is to promote the synthesis 
of IgE through the actions of IL-4 on Ig isotype switching 
(7) and to enhance the differentiation, migration, and patho- 
biologic capacity of eosinophils through the actions of GM- 
CSF, IL-3, and IL-5 (8, 9). The IgE produced in asthmatic 
airways binds to Fc~RI on mast cells, priming them for ac- 
tivation by antigen. Mast cells arise from bone marrow pre- 
cursors,  enter  the  circulation  as  non-metachromatically 
staining,  agranular,  CD34 +,  c-kit +,  and  F%I<I + mononu- 
clear leukocytes (10),  and localize to mucosal and submu- 
cosal  sites  such as the bronchi.  Once localized, these lin- 
eage-committed immature mast cells undergo tissue-specific 
differentiation along with maturation and expansion. Their 
development and movement involves growth  factors and 
cytokines derived from both structural and hematopoietic 
cells in their microenvironment. The mast cells that further 
migrate into the luminal space, and which can be recovered 
by bronchoalveolar lavage,  are  primed  for an  augmented 
activation response (11).  Mast cells also elaborate IL-4 (12, 
13), which favors conversion ofT cells to the TH  2 pheno- 
type, and IL-5 (14), which contributes to eosinophilopoie- 
sis  and  to  the  priming  of eosinophils  for augmented  re- 
sponses.  Once  recruited  from  the  circulation,  mature 
eosinophils, in the presence of"asthmatic" cytokines, con- 
vert to an autoaggressive phenotype (15,  16),  termed "hy- 
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podense" because of a change in eosinophil density gradi- 
ent  sedimentation  characteristics.  Hypodense  eosinophils 
are  primed  for  ligand-initiated  generation  of increased 
amounts  of superoxide and cysteinyl leukotrienes and for 
cytotoxic effects on bystander target cells (15,  16). Further- 
more,  eosinophils  may participate  in  a  positive  feedback 
loop by generating  eosinophil-active cytokines,  including 
IL-5, IL-3, and GM-CSF (17,  18). 
Although these anatomic characteristics of the asthmatic 
airway wall are well established, we can only speculate on 
the mechanisms that link airway inflammation and the al- 
tered physiology of asthma; our fullest understanding of  these 
mechanisms is that of the allergen-driven asthmatic reaction. 
As described above, exposure to allergen favors the synthe- 
sis  of IgE;  the binding of IgE  results  in  immunologically 
specific sensitization of mast cells, monocytes/macrophages, 
eosinophils, and basophils.  It is important to note that ex- 
pression  of the  high  affinity receptor for IgE,  Fc~RI,  by 
eosinophils and monocytes appears to be limited to particu- 
lar pathobiologic states, of  which atopy is prominent (19-21). 
When activated, these cells elaborate mediators of inflamma- 
tion,  including histamine,  leukotrienes, lipoxins,  platelet- 
activating factor, and various proteases into  the  local mi- 
croenvironment (22-29). They also secrete cytokines, which 
amplify the response and perpetuate the asthmatic pheno- 
type by aiding  in  the  recruitment of more  inflammatory 
bone marrow-derived cells and by having additional pro- 
inflammatory effects on smooth muscle and other resident 
cells (30-36). Together, these mediators and cytokines trans- 
duce the physiologic changes that we recognize as asthma, 
namely,  airway obstruction and hyperresponsiveness. The 
latter is  an  important phenotypic characteristic  of asthma 
and is recognized clinically as an obstructive physiologic re- 
sponse to a bronchoconstrictor stimulus that would be in- 
nocuous in an individual without asthma. Airway hyperre- 
sponsiveness is thought to result from some combination of 
submucosal edema, airway epithelial infiltration with eosi- 
nophils  and  lymphocytes,  damage  to  bronchial  epithelial 
cells with loss of regulatory mechanisms for mediator inac- 
tivation, and direct effects of mast cell-derived mediators, 
especially secretory granule neutral proteases and the  cys- 
teinyl leukotrienes. 
Although the chain of events leading to asthma is clearly 
complex, IL-4 and IL-5 have emerged as important partici- 
pating cytokines. Their relative importance in linking the 
cellular events noted above with airway hyperresponsive- 
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Figure  1.  Putative mechanisms of 
mast cell- and eosinophil-dependent 
airway  hyperresponsiveness. In  the 
sensitization phase, antigen  is pro- 
cessed by professional APC  such as 
the macrophage (M@). Presentation 
of certain peptides by APC, in the 
context of the appropriate cytokines 
and MHC, drives the clonal expan- 
sion ofTH  2 cells that elaborate IL-4, 
IL-3, IL-5, and GM-CSF.  IL-4 di- 
rects a switch in the Ig synthesis  by B 
cells to  IgE, which  is released and 
bound to mast cells, and under cer- 
tain  conditions  to  eosinophils and 
monocytes, through the high affinity 
IgE receptor. In the activation phase, after challenge with the relevant antigen, mast cells  release  preformed constituents of  their secretory granules, newly 
synthesized  bioactive lipids,  and induced cytokines. Of these mediators,  tryptase and the cysteinyl  leukotrienes may elicit airway hyperresponsiveness.  Mast 
cell-derived TNF-~x may contribute to the inflammatory  response through the upregulation of endothelial cell  adhesion molecules to localize eosinophils 
and T cells. IL-3, IL-5, and GM-CSF, which potentially activate, prime, and recruit eosinophils (Eos) to the site of allergic inflammation, are predomi- 
nantly T cell-derived, but the mast cell can contribute IL-5 and the eosinophil the entire triad. Eosinophil-derived granule contents, such as major basic 
protein (MBP) and eosinophil cationic protein (ECP), which damage the epithelium, and leukotrienes may elicit airway hyperresponsiveness.  Both 
strain-related genetic factors and the sensitization  procedures will determine the microenvironmental factors that regulate the prominence and pathobio- 
logic function of the critical cell types in allergic  inflammation. 
hess,  however,  has  not  been  established.  Indeed,  there  is 
currently no  way  to  definitively test their  role  in  human 
asthma since such tests require the ability to prevent either 
the  formation  or  the  action  of these  moieties  at  critical 
states in the development of atopy. Because of the impor- 
tance  of  understanding  the  role  of  these  cytokines  in 
asthma,  investigators  have  turned  to  animal  models  of 
asthma.  Murine  models are  currently the  most  useful be- 
cause  mice  develop  airway hyperresponsiveness after  sys- 
temic  allergen  sensitization  followed  by  repeated  aerosol 
challenge and because specific reagents are available for ma- 
nipulation of the murine immune system, including immu- 
nologically relevant transgenic or "knockout" mice. 
Two papers in this issue (37, 38) report studies in which 
the roles of IL-4 and IL-5 in the pathologic and physiologic 
changes  of asthma  were  explored  in  murine  models.  In 
both  studies,  airway  responsiveness  was  used  as  an  out- 
come indicator.  It is generally accepted that  credible ani- 
mal  models  of asthma  must  express  airway  hyperrespon- 
siveness  (39)  and  that  experimental  manipulations  that 
modify airway responsiveness can provide useful informa- 
tion on the importance of specific mechanisms in modifying 
airway responsiveness. Investigators in each study altered air- 
way  responsiveness by  manipulating  the  cytokines  in  the 
microenvironment  of the  airways.  What  is  intriguing  is 
that  Corry  et  al.  implicate  IL-4  as  the  key  cytokine  and 
provide  data  indicating that  hyperresponsiveness  can  oc- 
cur independently of IL-5 and eosinophils, whereas Foster 
et al. provide equally convincing evidence that [L-5 is the 
critical cytokine. Resolution of this apparent paradox pro- 
vides clues about the mechanisms that link both cytokines 
to airway responsiveness. 
Foster and  colleagues probe  the  role  of IL-5  in  airway 
responsiveness. They first demonstrate that they can induce 
airway  hyperresponsiveness  in  C57BL/6  mice  by  intra- 
peritoneal injection of antigen (50 Dg OVA in Alhydrogel) 
followed by repeated exposure to aerosols generated from 
antigen solutions (10  btg/ml OVA).  They show  that  IL-5 
knockout mice fail to develop airway hyperresponsiveness 
when sensitized with the same regimen and that when these 
mice are "reconstituted" for IL-5 with the use of recombi- 
nant vaccinia viruses expressing a cDNA for this cytokine, 
the eosinophils return. The investigators do not state whether 
the mice reacquired the capacity to develop airway hyper- 
responsiveness after antigen sensitization. The investigators 
did not report experiments in which IL-4 was manipulated, 
but  they demonstrated that  the  IL-5 knockout  mice pro- 
duced normal amounts of IgE in response to antigen sensi- 
tization.  Because  the  modifications in  airway responsive- 
ness were paralleled by changes in airway eosinophilia, the 
investigators conclude "that  IL-5 and eosinophils are cen- 
tral mediators in the pathogenesis of allergic lung disease." 
Corry and coworkers took a similar approach to creating 
experimental inflammation; BALB/c mice were  sensitized 
by the subcutaneous injection of antigen (25 ~g OVA with 
alum weekly for 4 wk) followed by repeated airway expo- 
sure  to  aerosols.  This  regimen  induced  airway  hyperre- 
sponsiveness. Mice that  were  treated  either with  an  mAb 
that depleted CD4 § T  cells or with an antibody against IL-4 
during the sensitization phase of the protocol, but not dur- 
ing subsequent inhalation challenge, failed to develop airway 
responsiveness. In contrast, mice treated with a neutralizing 
anti-IL-5 mAb had marked inhibition of airway eosinophilia 
but developed airway hyperresponsiveness when appropri- 
ately sensitized. They conclude "the  data .  .  . do not sup- 
port a  role for either IL-5 or eosinophils in mediating the 
acute airway hyperactivity." 
How can these two seemingly conflicting studies be re- 
solved? The answer,  we believe, lies in understanding that 
the same physiologic phenotype may be achieved through at 
least two  distinct cellular mechanisms.  One  such  mecha- 
nism could be through the IgE-stimulated activation of mast 
cells. For example,  airway hyperresponsiveness can be in- 
duced in mice by anti-IgE by a mechanism that is mast cell 
2  Commentary dependent (40). This indicates that IgE-mediated activation 
of mast cells initiates a sequence of events that can produce 
airway hyperresponsiveness. We believe that this sequence 
of events occurred in the model used by Corry et al. They 
used BALB/c  mice, which  are  "high  IgE" responders,  as 
their primary experimental animal. Their sensitization pro- 
tocols increased the levels of IL-4 and IgE in these mice, 
and  treatment  with  an  anti-IL-4 mAb  prevented  the  in- 
crease in IL-4 and airway hyperresponsiveness. Importantly, 
they  also  showed  that  this  sequence  of events  leading  to 
airway  hyperresponsiveness is  independent  of eosinophils 
and IL-5. 
If only one cellular mechanism could lead to airway hy- 
perresponsiveness,  there  would  be  little  need  for further 
discussion.  Foster et al.,  however, clearly demonstrate that 
airway hyperresponsiveness can be induced  in  the  mouse 
by an eosinophil- and IL-5-dependent mechanism, thereby 
elucidating  an  alternative  cellular pathway leading  to  the 
same physiological response. We believe that the choice of 
the C57BL/6  mouse as the experimental species by Foster 
et al. was a fortunate one, as this strain has a number of ge- 
netic defects that potentially prevented induction of airway 
hyperresponsiveness by the pathway documented by Corry 
et  al.  and  thus  allowed  recognization  of the  eosinophil- 
dependent pathway. 
What is special about the C57BL/6  mouse? It has been 
established,  through  linkage  analysis  in  a  cross  with  the 
naturally  hyperresponsive  A/J  mouse,  that  a  locus  on 
mouse  chromosome  17,  Bhr3,  which  maps  close  to  the 
gene for mouse mast cell protease 7, can confer constitutive 
airway hyperresponsiveness  on  the  naturally  hyporespon- 
sive C57BL/6 mouse (41). Analysis of the gene encoding mu- 
rine mast cell protease 7, which is a tryptase-like molecule 
(42,  43),  has demonstrated a point mutation that prevents 
the C57BL/6 mouse from producing this mast cell protease 
(44,  45).  Exogenously admininstered  tryptase  can  induce 
airway hyperresponsiveness (46),  in part through  its  enzy- 
matic capacity to cleave and inactivate vasoactive intestinal 
peptide, an endogenous bronchodilator (47). The C57BL/6 
strain is also  deficient in  the low molecular weight secre- 
tory phospholipase A 2 (48);  this  enzyme has  been  impli- 
cated in facilitating exocytosis in  mast cells  by generating 
lysophospholipids for fusion of the perigranular and plasma 
membranes (49)  and in providing some of the arachidonic 
acid used for eicosanoid biosynthesis (50,  51). We therefore 
speculate  that because of these  and perhaps other genetic 
deficiencies, the C57BL/6 mouse is resistant to the induc- 
tion  of mast  cell-dependent  airway  hyperresponsiveness. 
Perhaps because the mechanisms discovered by Corry et al. 
were genetically attenuated in the host species used by Fos- 
ter et al., the latter group came upon a series of sensitization 
maneuvers that recruited eosinophils into  the  airways and 
activated them in such a way as to induce hyperresponsive- 
ness.  Such  mechanisms include  the  production  of leuko- 
trienes or the release of major basic protein  (52).  Had the 
C57BL/6 mouse not been deficient in critical constituents, 
it is likely the capacity of eosinophils to mediate such an ef- 
fect in an allergen model would have gone undiscovered. 
The attempt to reconcile the differences in the two mod- 
els of airway hyperreactivity based on the role of the mast 
cell is not entirely satisfactory. One still has to explain the 
absence  of hyperresponsiveness in  the  BALB/c  strain  in 
the presence of marked tissue eosinophilia after treatment 
with  antibodies  to  IL-4 during  the  sensitization protocol. 
Perhaps the eosinophils are not primed because of a  defi- 
ciency of the requisite cytokine(s) at the critical tissue sites 
that results from differences in the strain,  the sensitization 
protocols, or both. The sensitization regimen used by Fos- 
ter  et  al.  (37)  induced  airway hyperresponsiveness in  the 
C57BL/6 strain, whereas that used by Corry et al. (38)  did 
not.  The differences in  the  relative  contributions  of IL-4 
and IL-5 to the two models may reside in some combina- 
tion of events, both inborn and acquired through sensitiza- 
tion,  which  regulate  the  cytokine  profile  and  hence  the 
critical cellular elements of the acquired airway hyperreac- 
tivity.  Despite the frustration  of our failure to completely 
reconcile the two studies, together they demonstrate clearly 
that there are multiple cellular pathways to the same physio- 
logic phenotype. 
If we extend this line of thinking to human asthma, we 
must conclude that multiple pathways can lead to the same 
clinical  phenotype,  namely  airway  hyperresponsiveness. 
Airway hyperresponsiveness can be induced in humans by 
allergen exposure, and this phenotype also can be expressed 
in the absence of eosinophilia by infection with certain vi- 
ruses (53)  or exposure to ozone (54).  Thus, the reports by 
Foster et al. and Corry et al.,  through a fortunate choice of 
experimental strain and sensitization protocols, provide rel- 
atively "pure" examples of eosinophil-dependent and eosi- 
nophil-independent pathways to the same clinical phenotype. 
Since  individuals  with asthma differ in their development 
of airway hyperresponsiveness, we  now have a  firm bio- 
logic basis for such differences. 
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